Glycomantra Inc.
Catonsville, MD
- UEI
- GJJRLDPAL8M9
- CAGE
- 796D7
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 1450 S Rolling Rd #4047, Halethorpe, MD 21227, USA
- Website
- glycomantra.com
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Thetis Pharmaceuticals LLC | Deep River, CT | — |
| Ceria Therapeutics Inc. | Tucson, AZ | 325412 Pharmaceutical Preparation Manufacturing |
| Creative Biotherapeutics LLC | Gurnee, IL | — |
| Eldec Pharmaceuticals, Inc. | Durham, NC | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Trethera Corp | Los Angeles, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Glycomantra Inc. is a biologics company developing novel therapeutics for unmet medical needs in metastatic castration resistant prostate cancer, NASH liver fibrosis, and type 2 diabetes. The company utilizes galectin 3, a protein involved in cancer progression, metastasis, and inflammation, as a therapeutic target.
The company has received multiple federal grant awards from agencies like the National Institutes of Health (NIH) to research and develop galectin-3 inhibitors for treating COVID-19, COVID-19 impacted type 2 diabetes, and insulin resistance in type 2 diabetes. One major project involved investigating a potent galectin-3 antagonist called TFD100 for treating COVID-19 and COVID-19 impacted type 2 diabetes in a humanized mouse model with human ACE-2 receptors. Another significant grant supported preclinical studies of TFD100 to overcome insulin resistance in type 2 diabetes, including pharmacokinetic/pharmacodynamic studies, efficacy studies in obese animal models, and GMP production for future toxicology studies. The ultimate goal was to enable an Investigational New Drug application submission to the FDA for initiating clinical trials of TFD100 in humans with type 2 diabetes.
Quick answers
Is Glycomantra Inc. registered in SAM.gov?
Yes. Glycomantra Inc.'s SAM.gov registration is active through March 11, 2027.
What is Glycomantra Inc.'s most recent federal award?
Glycomantra Inc.'s most recent federal grant award is Targeting galectin-3 to intervene covid-19 (R43AI162182), from National Institute of Allergy and Infectious Diseases (NIH), on August 17, 2022.
On GovTribe
See Glycomantra Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors